Recent Updates
Recently added Catalysts

antisense oligonucleotide

Phase 1

Progressive Supranuclear Palsy (PSP) | Small molecule | Neurology |Novartis AG|Last Updated: Dec 24, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment59
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04539041Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear PalsyPHASE1 COMPLETED 59Feb 16, 2021Oct 17, 2024Dec 24, 202512 United States, Canada +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of adverse events and serious adverse events
Baseline up to approximately one year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

Adverse events will be collected at clinical visits and other contacts. All abnormalities from safety assessments (physical exams and neurological exams and clinical safety labs) considered clinically significant will be recorded as adverse events

Change in severity scores for Columbia-Suicide Severity Rating Scale (C-SSRS)
Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire that prospectively assesses Suicidal Ideation and Suicidal Behavior. The C-SSRS must be administered at visits. If, at any time after "screening and/or baseline" version, the score is "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS or "yes" on any item of the Suicidal Behavior section, the participant must be referred to a mental health care professional for further assessment and/or treatment.

Levels of infection indicators in Cerebrospinal fluid (CSF)
Baseline up to approximately 1 year (3-month treatment plus 9-month follow-up or 9-month treatment plus 3-month follow-up)

CSF safety labs measure levels of proteins, glucose, lactate and white blood cell counts with differential indicating infections.

Secondary Endpoints
Concentrations of NIO752 in blood plasma
From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses
Concentrations of NIO752 in CSF
From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses
Cmax, Ctrough in blood plasma
From the 1st dose administration (day 1), through study completion, where the longest duration would be approximately 1 year for those who receive 4 treatment doses
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Cohort A NIO752EXPERIMENTAL4 injections of NIO752 at dose A
Cohort B NIO752EXPERIMENTAL4 injections of NIO752 at dose B
PlaceboPLACEBO_COMPARATOR4 injections of placebo
Cohort C NIO752EXPERIMENTAL4 injections of NIO752 at dose C
Cohort D NIO752EXPERIMENTAL4 injections of NIO752 at dose D
Cohort E NIO752EXPERIMENTAL4 injections of NIO752 at dose E
Interventions
NameTypeDescription
antisense oligonucleotideDRUGsolution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
placeboDRUGplacebo for each dose level
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria: 1. Signed informed consent 2. Between 40 to 75 years old (inclusive) 3. Have PSP diagnosed for less than 5 years with a current classification of probable PSP Richardson syndrome, a progressive supranuclear palsy rating scale (PSPRS) score \< 40 and MOCA score \>17 at screening ...

Countries:United StatesCanadaGermanyUnited Kingdom
Unlock Eligibility Criteria